An eGFR of 26 mL/min/1.73 m² corresponds to CKD Stage 4.
With an eGFR of 26 mL/min/1.73 m², this patient has Stage 4 chronic kidney disease, defined as severe reduction in kidney function with eGFR 15-29 mL/min/1.73 m². 1
CKD Staging Framework
The K/DOQI guidelines establish clear GFR-based staging for chronic kidney disease 2, 1:
- Stage 1: eGFR ≥90 mL/min/1.73 m² with evidence of kidney damage
- Stage 2: eGFR 60-89 mL/min/1.73 m² with kidney damage
- Stage 3a: eGFR 45-59 mL/min/1.73 m²
- Stage 3b: eGFR 30-44 mL/min/1.73 m²
- Stage 4: eGFR 15-29 mL/min/1.73 m² (severe reduction)
- Stage 5: eGFR <15 mL/min/1.73 m² or on dialysis (kidney failure)
Clinical Significance of Stage 4 CKD
At this level of kidney function, the patient has lost approximately 75-85% of normal kidney function 2. Stage 4 CKD represents severe kidney disease requiring nephrology referral and preparation for potential kidney replacement therapy 3, 4.
Key Clinical Actions at Stage 4:
- Mandatory nephrology referral - patients with eGFR <30 mL/min/1.73 m² should be evaluated by a nephrologist 3
- Preparation for renal replacement therapy - dialysis or transplantation planning should begin 5, 6
- Increased monitoring frequency - complications of CKD escalate significantly at this stage 2
- Medication dose adjustments - most drugs require dosing modifications at eGFR <30 2
Important Caveats:
The diagnosis of CKD requires persistence of reduced eGFR for ≥3 months 1, 7. A single measurement of eGFR 26 does not definitively establish Stage 4 CKD without:
- Repeat measurement confirming the reduced eGFR persists
- Assessment for acute kidney injury or reversible causes
- Evaluation of albuminuria status (UACR), which provides additional prognostic information 3, 4
The combination of eGFR and albuminuria provides the most accurate risk stratification - a patient with eGFR 26 and high albuminuria (≥300 mg/g) has substantially higher risk of progression to kidney failure and cardiovascular events than one with the same eGFR but no albuminuria 3, 7, 4.
At Stage 4, the adjusted hazard ratio for mortality is significantly elevated, and the 10-year risk of progressing to end-stage renal disease requiring dialysis is substantial 8. This underscores the critical importance of aggressive management of modifiable risk factors including blood pressure control, use of RAS inhibitors, SGLT2 inhibitors (if eGFR ≥20), and cardiovascular risk reduction 3, 7, 4.